Boston Scientific Ends Aortic Valve System Sales

Boston Scientific has announced the discontinuation of global sales and halted regulatory efforts for its ACURATE neo2 and Prime aortic valve systems due to increased regulatory demands and high costs. Despite the strategic setback, the company remains confident in meeting its previously issued sales and adjusted EPS guidance for the second quarter and full-year 2025, though it has not reaffirmed GAAP EPS guidance. Following the announcement, Boston Scientific shares declined and underperformed the broader market. Analysts remain positive on the company's broader strategy, with upward earnings estimate revisions and reported revenue growth of 19.36% over the past year. The company has stated it can manage the discontinuation's impact without jeopardizing 2025 financial targets, but acknowledges associated risks and uncertainties. Additionally, unrelated to Boston Scientific, Performance Food Group received a reaffirmed Buy rating from Citi.